People with early Alzheimer's now have two ways to start Leqembi: a weekly at-home injection or the original IV infusion schedule. The FDA approved the subcutaneous autoinjector, called LEQEMBI IQLIK, as a starting-dose option on July 13, 2026, so new patients no longer have to begin treatment at an infusion center, according to Practical Neurology. Both routes deliver the same drug, lecanemab, which clears amyloid plaque from the brain in people with mild cognitive impairment or mild dementia due to Alzheimer's disease. The choice now comes down to logistics, monitoring routine, and personal preference rather than a difference in who qualifies.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Practicalneurology — Use this primary source to verify the official guidance.
- Explore the official data from Healio — Use this primary source to review the underlying data.
Table of Contents
- What Changed With the July 2026 Approval
- How the Two Dosing Schedules Actually Work
- Is At-Home Dosing as Effective as IV?
- Weighing the Practical Tradeoffs
- What the Decision Means for Patients and Caregivers
- Frequently Asked Questions
What Changed With the July 2026 Approval
Until this decision, every new Leqembi patient had to complete 18 months of biweekly IV infusions before switching to an at-home option. The FDA's August 29, 2025 approval covered subcutaneous dosing only for maintenance, after the IV phase was already finished, according to Reuters via Precision Medicine Online.
The 2026 approval removes that requirement. A patient can now start on the subcutaneous autoinjector from day one, skipping IV infusions entirely unless they or their clinician prefer the infusion route, as reported by Practical Neurology.
How the Two Dosing Schedules Actually Work
The at-home regimen starts with 500 mg given weekly, split into two 250 mg injections under the skin. After 18 months, patients either continue on a 360 mg weekly subcutaneous maintenance dose or switch over to IV infusion maintenance, according to Healio.
The traditional IV path still exists for patients who want it: infusions typically run every two to four weeks and take about an hour at a clinic or infusion center, per Fierce Pharma and 2minutemedicine. By contrast, the autoinjector delivers its dose in about 15 seconds and can be given by the patient or a caregiver at home.
- At-home start: 500 mg weekly (two 250 mg injections), 15-second delivery, no clinic visit required
- IV start: infusion every 2–4 weeks, roughly one hour per visit at a clinic or infusion center
- After 18 months: continue subcutaneous maintenance at 360 mg weekly, or switch to IV maintenance
Is At-Home Dosing as Effective as IV?
The FDA's approval rests on pharmacokinetic sub-study data showing that once-weekly subcutaneous dosing produces drug exposure equivalent to IV dosing, which supports comparable amyloid-clearing effect, according to Healio. That equivalence is the basis for letting patients start treatment at home rather than only switching to it later.
Safety data point in a similar direction. The subcutaneous route showed a profile broadly similar to IV infusion, with injection-site reactions that were mostly localized, while systemic reactions were reported less often than with IV administration, per Healio. Neither route changes the underlying monitoring plan: both still require the standard MRI schedule for ARIA, short for amyloid-related imaging abnormalities, a known side effect involving brain swelling or small bleeds that lecanemab treatment can cause.
Weighing the Practical Tradeoffs
The biggest practical difference is time and travel. A weekly at-home injection eliminates the drive to an infusion center and the roughly hour-long seated infusion, which matters for patients with mobility limits or caregivers managing transportation, as noted in reporting from Fierce Pharma and 2minutemedicine. IV infusion, in exchange, puts a clinician in the room at the exact moment of dosing, which some patients and families still prefer given that lecanemab carries ARIA risk.
Cost is comparable between the two paths. Eisai priced the subcutaneous autoinjector at about $19,500 a year for maintenance, which the company says reflects lower delivery costs than running an infusion program, according to Practical Neurology. The initiation-dose version of LEQEMBI IQLIK is expected to reach U.S. specialty pharmacies by late August 2026.
- No home-infusion equipment or IV line needed, since the autoinjector is a simple subcutaneous injection
- Weekly dosing at home still requires the same ARIA MRI monitoring schedule as IV patients
- A switch from one route to the other is possible after the 18-month initiation period, not locked in at the start
What the Decision Means for Patients and Caregivers
The Alzheimer's Association publicly welcomed the approval, describing it as removing the IV-only barrier that had required every new patient to begin treatment at an infusion site before any at-home option existed, according to the Alzheimer's Association. For families managing a long drive to the nearest infusion center, or a patient who resists repeated IV needle placement, that removal opens a realistic alternative from the first dose.
The decision point for a patient and their clinician now comes down to self-administered weekly home injections, which are faster and require no infusion-site travel, against IV infusion's longer-established dosing history and in-person clinical supervision at the moment of dosing — both routes carrying the same ARIA monitoring requirement either way, per synthesis of Healio reporting. A clinician can switch a patient between routes at the 18-month mark if the first choice stops fitting their situation.
Frequently Asked Questions
Can a new patient skip IV infusion entirely and start Leqembi at home?
Yes. The July 13, 2026 approval lets patients begin with the subcutaneous autoinjector instead of IV infusion, according to Practical Neurology.
Does starting at home mean less monitoring for side effects?
No. Both the at-home and IV routes require the same ARIA MRI monitoring schedule, per Healio.
What happens after the first 18 months of treatment?
Patients continue on a 360 mg weekly subcutaneous maintenance dose or switch to IV infusion maintenance, according to Healio.
Does the at-home version cost more than IV infusion?
The subcutaneous autoinjector is priced at about $19,500 a year for maintenance, which Eisai says reflects lower delivery costs than infusion, per Practical Neurology.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: How People With Early Alzheimer’s Can Compare Treatment Routes
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- Cross-Cultural Dementia Risk Programs After LatAm-FINGERS 2026: How Adults in Midlife Can Avoid Overreading the Headline
